glp-1 and parkinson's Frontiers GLP-1 does not slow Parkinson's

Removal of bioactive GLP-1 is a consequence of N-terminal proteolysis catalyzed by dipeptidyl peptidase IV (DPP IV or DPP4)

Rather than treating coverage as all-or-nothing, Fronstin and Williams pointed to more targeted models, including limiting access to higher-risk populations, requiring prior authorization, setting reassessment checkpoints, and pairing medication coverage with nutrition or behavioral support

Self-adjusting doses undermines both safety and efficacy and is one of the clearest arguments for supervised rather than unsupervised GLP-1 use

We hope that we can refine this method to be a noninvasive continuous glucose monitoring sensor. With more testing, the researchers hope spectroscopy can become an alternative method to test glucose levels in patients in clinical care settings who are not capable of frequent blood draws and, one day, in other settings as the technology becomes smaller and more portable